FORM OF LOCK-UP AGREEMENTLock-Up Agreement • December 16th, 2019 • China SXT Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
CHINA SXT PHARMACEUTICALS, INC.Securities Purchase Agreement • December 16th, 2019 • China SXT Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Reference is hereby made to (a) that certain Securities Purchase Agreement, dated as of April 16, 2019 (as amended, restated or otherwise modified from time to time prior to the date hereof, the “SPA”), by and among CHINA SXT PHARMACEUTICALS, INC., a company organized under the laws of the British Virgin Islands (the “Company”), the undersigned (the “Investor”) and the other buyers signatory thereto (the “Buyers”), pursuant to which, among other things, the Company sold, and the Investor, in its capacity as a Buyer, purchased (i) a Series A Note (as defined in the Forbearance Agreement), (ii) a Series B Senior Secured Convertible Note (as defined in the Forbearance Agreement), (iii) a Series A Warrant to purchase 298,329 of the Company’s ordinary shares equal to 50% of the shares issuable upon conversion of the Series A Notes, and (D) a Series B Warrant to purchase 149,165 of the Company’s ordinary shares equal to 50% of the shares issuable upon conversion of the Series B Notes (Series
FORM OF MUTUAL RELEASEMutual Release • December 16th, 2019 • China SXT Pharmaceuticals, Inc. • Pharmaceutical preparations
Reference is hereby made to (a) that certain Securities Purchase Agreement, dated as of April 16, 2019 (as amended, restated or otherwise modified from time to time prior to the date hereof, the “Securities Purchase Agreement”), by and among CHINA SXT PHARMACEUTICALS, INC., a company organized under the laws of the British Virgin Islands (the “Company”), [INVESTOR] (the “Investor”) and the other buyers signatory thereto (the “Buyers”), pursuant to which, among other things, the Company sold, and the Investor, in its capacity as a Buyer, purchased (A) that certain Series A Senior Convertible Note, dated May 2, 2019, with an original principal amount of US$5,000,000 (as amended, restated or otherwise modified from time to time prior to the date hereof, the “Series A Note”), convertible into Ordinary Shares (as defined in the Securities Purchase Agreement) in accordance therewith and (B) that certain Series B Senior Secured Convertible Note, dated May 2, 2019, with an original principal a
FORM OF FORBEARANCE AND AMENDMENT AGREEMENTForbearance and Amendment Agreement • December 16th, 2019 • China SXT Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Forbearance and Amendment Agreement (“Agreement”) is made and entered into this 13th day of December, 2019, by and between, [INVESTOR] (the “Investor”) and CHINA SXT PHARMACEUTICALS, INC., a company organized under the laws of the British Virgin Islands (the “Company”) (collectively, the “Parties”).
